{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T11:35:35.254920+00:00","company":{"ticker":"CERO","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC."},"pagination":{"limit":100,"returned":100,"next_cursor":"2023-12-11T23:59:59+00:00|89169"},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Keystone Capital Partners, LLC","detail":"notes_offering","count":5,"first_seen":"2024-02-15T23:59:59+00:00","last_seen":"2026-05-01T23:59:59+00:00","evidence_fact_ids":[22022,24642,29179,32372,74655]},{"display_name":"Continental Stock Transfer and Trust Company","detail":"other","count":2,"first_seen":"2023-07-10T23:59:59+00:00","last_seen":"2024-01-05T23:59:59+00:00","evidence_fact_ids":[83291,132972]},{"display_name":"Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc.","detail":"merger","count":2,"first_seen":"2023-06-05T23:59:59+00:00","last_seen":"2024-02-06T23:59:59+00:00","evidence_fact_ids":[77056,143896]},{"display_name":"Phoenix Biotech Sponsor, LLC","detail":"credit_facility","count":2,"first_seen":"2022-12-07T23:59:59+00:00","last_seen":"2023-12-11T23:59:59+00:00","evidence_fact_ids":[89169,192729]},{"display_name":"Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13","detail":"equity_purchase","count":1,"first_seen":"2024-02-28T23:59:59+00:00","last_seen":"2024-02-28T23:59:59+00:00","evidence_fact_ids":[71246]},{"display_name":"Intrinsic Medicine, Inc.","detail":"merger","count":1,"first_seen":"2022-12-07T23:59:59+00:00","last_seen":"2022-12-07T23:59:59+00:00","evidence_fact_ids":[192728]},{"display_name":"OM Merger Sub, Inc., Intrinsic Medicine, Inc.","detail":"merger","count":1,"first_seen":"2022-10-31T23:59:59+00:00","last_seen":"2022-10-31T23:59:59+00:00","evidence_fact_ids":[202132]},{"display_name":"Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., CERo Therapeutics, Inc.","detail":"merger","count":1,"first_seen":"2024-02-14T23:59:59+00:00","last_seen":"2024-02-14T23:59:59+00:00","evidence_fact_ids":[75118]},{"display_name":"SRX Health Solutions, Inc.","detail":"notes_offering","count":1,"first_seen":"2026-05-29T20:05:17+00:00","last_seen":"2026-05-29T20:05:17+00:00","evidence_fact_ids":[84142]},{"display_name":"certain Intrinsic stockholders","detail":"asset_purchase","count":1,"first_seen":"2022-12-07T23:59:59+00:00","last_seen":"2022-12-07T23:59:59+00:00","evidence_fact_ids":[192730]}],"lender":[{"display_name":"Keystone Capital Partners, LLC","detail":"convertible_notes","count":4,"first_seen":"2026-02-13T23:59:59+00:00","last_seen":"2026-05-01T23:59:59+00:00","evidence_fact_ids":[21345,30098,32238,33664]},{"display_name":"Phoenix Biotech Sponsor, LLC","detail":"loan","count":1,"first_seen":"2023-12-11T23:59:59+00:00","last_seen":"2023-12-11T23:59:59+00:00","evidence_fact_ids":[89174]},{"display_name":"SRX Health Solutions, Inc.","detail":"convertible_notes","count":1,"first_seen":"2026-05-29T20:05:17+00:00","last_seen":"2026-05-29T20:05:17+00:00","evidence_fact_ids":[54283]}],"ma_counterparty":[{"display_name":"CERo Therapeutics, Inc.","detail":"acquisition","count":1,"first_seen":"2024-02-15T23:59:59+00:00","last_seen":"2024-02-15T23:59:59+00:00","evidence_fact_ids":[74657]},{"display_name":"Phoenix Biotech Acquisition Corp.","detail":"change_of_control","count":1,"first_seen":"2024-02-27T23:59:59+00:00","last_seen":"2024-02-27T23:59:59+00:00","evidence_fact_ids":[71814]}]},"facts":[{"fact_type":"equity_issuance","fact_key":"e6c7916263369b289ab9adf2ed66f4dc5d18de8e","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-05-29T20:05:17+00:00","payload":{"action":"private_placement","consideration_text":"$750,000","effective_date":"2026-05-28","item_codes_triggered":["3.02"],"purchaser":"SRX Health Solutions, Inc.","security_type":"convertible_note","shares_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to SRX Health Solutions, Inc. for $750,000.","evidence_excerpt":"On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Health Solutions, Inc. (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-062802","anchor_url":"https://secwatch.observer/filing/0001213900-26-062802#claim-e6c7916263369b289ab9adf2ed66f4dc5d18de8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026062802/0001213900-26-062802-index.htm"},{"fact_type":"material_agreement","fact_key":"0d4b2b3f1fa786fef804b7c7c712f8d71426e41c","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-05-29T20:05:17+00:00","payload":{"action":"entry","agreement_name":"Note","agreement_type":"notes_offering","counterparty":"SRX Health Solutions, Inc.","effective_date":"2026-05-28","item_codes_triggered":["1.01"],"value_text":"$750,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Note with SRX Health Solutions, Inc. valued at $750,000 (effective 2026-05-28).","evidence_excerpt":"On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Health Solutions, Inc. (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-062802","anchor_url":"https://secwatch.observer/filing/0001213900-26-062802#claim-0d4b2b3f1fa786fef804b7c7c712f8d71426e41c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026062802/0001213900-26-062802-index.htm"},{"fact_type":"debt_financing","fact_key":"c3d2736e19bdd40f779a84b3fc4c4f171e1d71bb","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-05-29T20:05:17+00:00","payload":{"counterparty":"SRX Health Solutions, Inc.","effective_date":"2026-05-28","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"10% per annum","item_codes_triggered":["2.03"],"maturity_text":"May 28, 2027","principal_text":"$937,500"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $937,500 with SRX Health Solutions, Inc. at 10% per annum maturing May 28, 2027.","evidence_excerpt":"On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Health Solutions, Inc. (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-062802","anchor_url":"https://secwatch.observer/filing/0001213900-26-062802#claim-c3d2736e19bdd40f779a84b3fc4c4f171e1d71bb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026062802/0001213900-26-062802-index.htm"},{"fact_type":"equity_issuance","fact_key":"a2143d41a0ccf36e2ea71d93611d4f1842a2cfe7","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-05-01T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$400,000","effective_date":"2026-04-27","item_codes_triggered":["3.02"],"purchaser":"Keystone Capital Partners, LLC","security_type":"convertible_note","shares_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for $400,000.","evidence_excerpt":"On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-050951","anchor_url":"https://secwatch.observer/filing/0001213900-26-050951#claim-a2143d41a0ccf36e2ea71d93611d4f1842a2cfe7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm"},{"fact_type":"material_agreement","fact_key":"c96ab91b8a36a1ee3a5ba2adc2ccc7e3a30078b0","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-05-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Note","agreement_type":"notes_offering","counterparty":"Keystone Capital Partners, LLC","effective_date":"2026-04-27","item_codes_triggered":["1.01"],"value_text":"$400,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $400,000 (effective 2026-04-27).","evidence_excerpt":"On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-050951","anchor_url":"https://secwatch.observer/filing/0001213900-26-050951#claim-c96ab91b8a36a1ee3a5ba2adc2ccc7e3a30078b0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm"},{"fact_type":"debt_financing","fact_key":"d09c3ea07a974940e7233133a9b69c1e1ce50f4f","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-05-01T23:59:59+00:00","payload":{"counterparty":"Keystone Capital Partners, LLC","effective_date":"2026-04-27","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"10% per annum","item_codes_triggered":["2.03"],"maturity_text":"April 27, 2027","principal_text":"$400,000, having a principal face value of $500,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $400,000, having a principal face value of $500,000 with Keystone Capital Partners, LLC at 10% per annum maturing April 27, 2027.","evidence_excerpt":"On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the \"Company\") issued and sold a convertible promissory note for an purchase price of $400,000, having a principal face value of $500,000 (the \"Note\") to Keystone Capital Partners, LLC (\"Lender\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-050951","anchor_url":"https://secwatch.observer/filing/0001213900-26-050951#claim-d09c3ea07a974940e7233133a9b69c1e1ce50f4f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm"},{"fact_type":"equity_issuance","fact_key":"cadd08f3e3d9459f379d7808a1c384750d69057e","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-04-14T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"purchase price of $350,000","effective_date":"2026-04-08","item_codes_triggered":["3.02"],"purchaser":"Keystone Capital Partners, LLC","security_type":"convertible_note","shares_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for purchase price of $350,000.","evidence_excerpt":"On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-043519","anchor_url":"https://secwatch.observer/filing/0001213900-26-043519#claim-cadd08f3e3d9459f379d7808a1c384750d69057e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026043519/0001213900-26-043519-index.htm"},{"fact_type":"debt_financing","fact_key":"083c34068eaf5086b053e6f1624e0c355fd070ce","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-04-14T23:59:59+00:00","payload":{"counterparty":"Keystone Capital Partners, LLC","effective_date":"2026-04-08","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"10% per annum","item_codes_triggered":["2.03"],"maturity_text":"April 9, 2027","principal_text":"$350,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $350,000 with Keystone Capital Partners, LLC at 10% per annum maturing April 9, 2027.","evidence_excerpt":"On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-043519","anchor_url":"https://secwatch.observer/filing/0001213900-26-043519#claim-083c34068eaf5086b053e6f1624e0c355fd070ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026043519/0001213900-26-043519-index.htm"},{"fact_type":"material_agreement","fact_key":"2d2188ed3529d5b0fe8db50a869c555d5ecfd5c0","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-04-14T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Note","agreement_type":"notes_offering","counterparty":"Keystone Capital Partners, LLC","effective_date":"2026-04-08","item_codes_triggered":["1.01"],"value_text":"$350,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $350,000 (effective 2026-04-08).","evidence_excerpt":"On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-043519","anchor_url":"https://secwatch.observer/filing/0001213900-26-043519#claim-2d2188ed3529d5b0fe8db50a869c555d5ecfd5c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026043519/0001213900-26-043519-index.htm"},{"fact_type":"equity_issuance","fact_key":"dec6d57a5d4af89df6b1f2d7896d818bd5ce32f5","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-03-11T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"purchase price of $750,000","effective_date":"2026-03-06","item_codes_triggered":["3.02"],"purchaser":"Keystone Capital Partners, LLC","security_type":"convertible_note","shares_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for purchase price of $750,000.","evidence_excerpt":"On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-025817","anchor_url":"https://secwatch.observer/filing/0001213900-26-025817#claim-dec6d57a5d4af89df6b1f2d7896d818bd5ce32f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm"},{"fact_type":"debt_financing","fact_key":"50dd6331f5e0f9b5b43fbc34b6c8db1986de03c7","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-03-11T23:59:59+00:00","payload":{"counterparty":"Keystone Capital Partners, LLC","effective_date":"2026-03-06","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"10% per annum","item_codes_triggered":["2.03"],"maturity_text":"August 6, 2027","principal_text":"$750,000 purchase price, $937,500 principal face value, up to $1,000,000 aggregate"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $750,000 purchase price, $937,500 principal face value, up to $1,000,000 aggregate with Keystone Capital Partners, LLC at 10% per annum maturing August 6, 2027.","evidence_excerpt":"On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-025817","anchor_url":"https://secwatch.observer/filing/0001213900-26-025817#claim-50dd6331f5e0f9b5b43fbc34b6c8db1986de03c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm"},{"fact_type":"material_agreement","fact_key":"dd698a7d3132bc338735127c2283fe682a049c05","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-03-11T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Convertible Promissory Note","agreement_type":"notes_offering","counterparty":"Keystone Capital Partners, LLC","effective_date":"2026-03-06","item_codes_triggered":["1.01"],"value_text":"Purchase price $750,000; principal face value $937,500; maximum aggregate borrowings $1,000,000; int"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Convertible Promissory Note with Keystone Capital Partners, LLC valued at Purchase price $750,000; principal face value $937,500; maximum aggregate borrowings $1,000,000; int (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001213900-26-025817","anchor_url":"https://secwatch.observer/filing/0001213900-26-025817#claim-dd698a7d3132bc338735127c2283fe682a049c05","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm"},{"fact_type":"equity_issuance","fact_key":"d948b32a0316b60582a0f644b908bf1b799cd3b5","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-02-13T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$750,000","effective_date":"2026-02-09","item_codes_triggered":["3.02"],"purchaser":"Keystone Capital Partners, LLC","security_type":"convertible_note","shares_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for $750,000.","evidence_excerpt":"On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-016474","anchor_url":"https://secwatch.observer/filing/0001213900-26-016474#claim-d948b32a0316b60582a0f644b908bf1b799cd3b5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm"},{"fact_type":"debt_financing","fact_key":"7a34263d5640eb41c9ca784b00694b3152f56b99","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-02-13T23:59:59+00:00","payload":{"counterparty":"Keystone Capital Partners, LLC","effective_date":"2026-02-09","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"10% per annum","item_codes_triggered":["2.03"],"maturity_text":"July 9, 2027","principal_text":"$750,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $750,000 with Keystone Capital Partners, LLC at 10% per annum maturing July 9, 2027.","evidence_excerpt":"On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-016474","anchor_url":"https://secwatch.observer/filing/0001213900-26-016474#claim-7a34263d5640eb41c9ca784b00694b3152f56b99","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm"},{"fact_type":"material_agreement","fact_key":"5599ea82aae7728cb06be2fd8e9c3822d722c54f","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-02-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Note","agreement_type":"notes_offering","counterparty":"Keystone Capital Partners, LLC","effective_date":"2026-02-09","item_codes_triggered":["1.01"],"value_text":"$750,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $750,000 (effective 2026-02-09).","evidence_excerpt":"On February 9, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-016474","anchor_url":"https://secwatch.observer/filing/0001213900-26-016474#claim-5599ea82aae7728cb06be2fd8e9c3822d722c54f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm"},{"fact_type":"auditor_change","fact_key":"fcf6967ef91680d9dded67eadeba28e14fbe892d","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-02-13T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Salberg & Company, P.A.","disagreement_text":null,"effective_date":"2026-02-13","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. engaged Salberg & Company, P.A. as its auditor.","evidence_excerpt":"The Company’s audit committee of the board of directors (the “Audit Committee”) approved the appointment of Salberg & Company, P.A. (“Salberg”) as the Company’s independent registered public accounting firm, effective following the finalization of the terms of an engagement letter therewith and execution thereof of February 11, 2026, with such appointment effective as of February 13, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-016474","anchor_url":"https://secwatch.observer/filing/0001213900-26-016474#claim-fcf6967ef91680d9dded67eadeba28e14fbe892d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm"},{"fact_type":"auditor_change","fact_key":"85b7fbee698b1ef13e0059de746abeacd36cb503","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-02-13T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Wolf & Company, P.C.","disagreement_text":null,"effective_date":"2026-02-13","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Salberg & Company, P.A."},"claim":"CERO THERAPEUTICS HOLDINGS, INC. dismissed Wolf & Company, P.C. as its auditor.","evidence_excerpt":"The Company’s audit committee of the board of directors (the “Audit Committee”) approved the decision to dismiss Wolf & Company, P.C. (“Wolf”), as the Company’s independent registered public accounting firm, effective as of February 13, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-016474","anchor_url":"https://secwatch.observer/filing/0001213900-26-016474#claim-85b7fbee698b1ef13e0059de746abeacd36cb503","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4491ff78ac9d73577ad20d8e9ab5e1b7c1ee2130","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-02-03T23:59:59+00:00","payload":{"company_response":"appeal to Council","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-01-29","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":[],"rules_cited_in_text":false},"claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding other.","evidence_excerpt":"January 29, 2026, after considering the written\nrecord in this matter, the Council issued its decision affirming the Panel’s decision to delist the Company’s securities from\nNasdaq. 1 SIGNATURES Pursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 3, 2026 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-011587","anchor_url":"https://secwatch.observer/filing/0001213900-26-011587#claim-4491ff78ac9d73577ad20d8e9ab5e1b7c1ee2130","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026011587/0001213900-26-011587-index.htm"},{"fact_type":"material_agreement","fact_key":"1ce6ed07435bcd75595177b2fa26f06ef8a08e20","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-12-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"other","counterparty":"an institutional investor (the \"Investor\")","effective_date":"2025-11-26","item_codes_triggered":["1.01"],"value_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Registration Rights Agreement with an institutional investor (the \"Investor\") (effective 2025-11-26).","evidence_excerpt":"Concurrent with the execution of the Purchase Agreement, the Company entered into a registration rights agreement with the Investor (the “Registration Rights Agreement”), pursuant to which the Company agreed to provide the Investor with customary registration rights related to the shares issued under the Registration Rights Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-116971","anchor_url":"https://secwatch.observer/filing/0001213900-25-116971#claim-1ce6ed07435bcd75595177b2fa26f06ef8a08e20","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025116971/0001213900-25-116971-index.htm"},{"fact_type":"material_agreement","fact_key":"7159a37d464b23c38af1f8cfd5627c4f51d02775","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-12-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"an institutional investor (the \"Investor\")","effective_date":"2025-11-26","item_codes_triggered":["1.01"],"value_text":"up to $14,591,939"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Purchase Agreement with an institutional investor (the \"Investor\") valued at up to $14,591,939 (effective 2025-11-26).","evidence_excerpt":"On November 26, 2025, the Company entered into a purchase agreement (the “Purchase Agreement”) with the Investor, pursuant to which the Company may issue and sell to the Investor, from time to time as provided in the Purchase Agreement, and the Investor shall purchase from the Company up to $14,591,939 of the Company’s outstanding shares of Common Stock, subject to the satisfaction of the conditions in the Purchase Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-116971","anchor_url":"https://secwatch.observer/filing/0001213900-25-116971#claim-7159a37d464b23c38af1f8cfd5627c4f51d02775","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025116971/0001213900-25-116971-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"323f38dd672d0083a3e90a0d7e877b513ee1a9ef","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-10-30T23:59:59+00:00","payload":{"company_response":"requested review by Nasdaq Listing and Hearing Review Council; commenced process for OTC Markets trading","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":"2025-10-31","exchange":"nasdaq","hearing_date":"2025-09-03","immediate_listing_effect":null,"minimum_requirement":"2500000","notice_date":"2025-10-29","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Rule 5550(b)","reported_value":null,"rule_numbers":["5550(b)"],"rules_cited_in_text":true},"claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"October 29, 2025, the Company received the determination of the Hearings Panel to deny the Company’s request for the continued\nlisting of its common stock. As a result, the common stock will be suspended from trading on Nasdaq at open of trading on October 31,\n2025. The Company has submitted a request for review of the Hearings Panel’s\ndecision by the Nasdaq Listing and Hearing Review Council (the “ Council ”). The Company has also commenced the\nprocess of seeking to trade its shares of common stock on the OTC Markets. However, the Company can provide no assurance that the review\nby the Counci","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-103661","anchor_url":"https://secwatch.observer/filing/0001213900-25-103661#claim-323f38dd672d0083a3e90a0d7e877b513ee1a9ef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025103661/0001213900-25-103661-index.htm"},{"fact_type":"governance_change","fact_key":"9a5b5ccfab8325d9ebf4abb0add1d5f7ac94e38a","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-10-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-10-14","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Designations establishing Series E convertible preferred stock"},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations establishing Series E convertible preferred stock (effective 2025-10-14).","evidence_excerpt":"On October 14, 2025, the Company filed the Certificate of Designations of Rights and Preferences of the Series E Preferred Stock (the “Certificate of Designations”) for the purpose of designating and establishing the Company’s Series E convertible preferred stock, par value $0.0001 per share (the “Series E Preferred Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-099560","anchor_url":"https://secwatch.observer/filing/0001213900-25-099560#claim-9a5b5ccfab8325d9ebf4abb0add1d5f7ac94e38a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025099560/0001213900-25-099560-index.htm"},{"fact_type":"equity_issuance","fact_key":"1ad1bd55ee77d256ad36a2ca50e71861f4a4fa91","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-10-14T23:59:59+00:00","payload":{"action":"pipe","consideration_text":"aggregate purchase price of up to $7 million","effective_date":"2025-10-14","item_codes_triggered":["3.02"],"purchaser":"certain accredited investors named therein (the \"PIPE Investors\")","security_type":"preferred_stock","shares_text":"up to 9,750 shares of the Company's Series E convertible preferred stock"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. issued up to 9,750 shares of the Company's Series E convertible preferred stock of preferred stock to certain accredited investors named therein (the \"PIPE Investors\") for aggregate purchase price of up to $7 million.","evidence_excerpt":"Pursuant to the Securities Purchase Agreement, up to 9,750 shares of the Company’s Series E convertible preferred stock, par value $0.0001 per share (the “ Series E Preferred Stock ”) shall be purchased for an aggregate purchase price of up to $7 million in one or more closings","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-098421","anchor_url":"https://secwatch.observer/filing/0001213900-25-098421#claim-1ad1bd55ee77d256ad36a2ca50e71861f4a4fa91","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025098421/0001213900-25-098421-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"30697d71548961127af7bd3cd54d156d4c9a1848","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-09-04T23:59:59+00:00","payload":{"company_response":"requested hearing to appeal; intends to submit plan to regain compliance","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":"2025-09-08","exchange":"nasdaq","hearing_date":"2025-09-03","immediate_listing_effect":null,"minimum_requirement":"$2,500,000","notice_date":"2025-08-28","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Rule 5550(b)","reported_value":null,"rule_numbers":["5550(b)","5815(d)(4)(B)"],"rules_cited_in_text":true},"claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b), 5815(d)(4)(B)).","evidence_excerpt":"August 28, 2025, CERo\nTherapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), received a letter from the staff at the\nNasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the\nminimum stockholders’ equity requirement of $2,500,000 (the “ Stockholders’ Equity Requirement ”)\nfor continued listing on the Nasdaq Capital Market (“ Nasdaq ”) set forth in Nasdaq Rule 5550(b). As previously disclosed,\nthe Company previously had been out of compliance with Nasdaq continued listing requirements until, on May 7","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-084498","anchor_url":"https://secwatch.observer/filing/0001213900-25-084498#claim-30697d71548961127af7bd3cd54d156d4c9a1848","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025084498/0001213900-25-084498-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"90cc61171890116683ef909c642eec57c5f1a7a4","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-06-13T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-06-11","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"June 11, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter (the “Bid\nPrice Requirement Letter”) from the Listing Qualifications Department (the “Staff”) at The Nasdaq Stock Market (“Nasdaq”)\nnotifying the Company that, for the 30 consecutive business day period between April 25, 2025 through June 9, 2025, the closing bid price\nfor the Company’s common stock, par value $0.0001 per share (the “Common Stock”), has been below the minimum $1.00 per\nshare required for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-054371","anchor_url":"https://secwatch.observer/filing/0001213900-25-054371#claim-90cc61171890116683ef909c642eec57c5f1a7a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025054371/0001213900-25-054371-index.htm"},{"fact_type":"governance_change","fact_key":"7b8f4a7ccd90ed7c23e39d9dfc22d839638c559b","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-06-11T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-13","item_codes_triggered":["5.03"],"summary_text":"The Company filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split of its common stock, effective June 13, 2025."},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: The Company filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split of its common stock, effective June 13, 2025 (effective 2025-06-13).","evidence_excerpt":"On June 11, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-053292","anchor_url":"https://secwatch.observer/filing/0001213900-25-053292#claim-7b8f4a7ccd90ed7c23e39d9dfc22d839638c559b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025053292/0001213900-25-053292-index.htm"},{"fact_type":"executive_change","fact_key":"739bae153d","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-06-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-04","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Andrew Albert Kucharchuk was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"the Company agreed to employ Mr. Kucharchuk as the Company’s Chief Financial Officer as of and from June 4, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-050055","anchor_url":"https://secwatch.observer/filing/0001213900-25-050055#claim-739bae153d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm"},{"fact_type":"executive_change","fact_key":"03bb5afadd","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-06-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-04","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Chris Ehrlich was appointed as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"the Company agreed to employ Mr. Ehrlich as the Company’s Chief Executive Officer as of and from June 4, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-050055","anchor_url":"https://secwatch.observer/filing/0001213900-25-050055#claim-03bb5afadd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm"},{"fact_type":"governance_change","fact_key":"4eb1f82da50ad2ad8f09434676e287514a6abae6","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-04-25T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-04-22","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Designations for Series D convertible preferred stock"},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations for Series D convertible preferred stock (effective 2025-04-22).","evidence_excerpt":"On April 22, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed the Certificate of Designations of Rights and Preferences of the Series D Preferred Stock (the “Certificate of Designations”) for the purpose of designating and establishing the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-035535","anchor_url":"https://secwatch.observer/filing/0001213900-25-035535#claim-4eb1f82da50ad2ad8f09434676e287514a6abae6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025035535/0001213900-25-035535-index.htm"},{"fact_type":"governance_change","fact_key":"4d653982e8fabae094561a163c06f05c06f30d20","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-01-06T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-01-08","item_codes_triggered":["5.03"],"summary_text":"Amended certificate of incorporation to effect a 1-for-100 reverse stock split"},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: Amended certificate of incorporation to effect a 1-for-100 reverse stock split (effective 2025-01-08).","evidence_excerpt":"On January 6, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-001156","anchor_url":"https://secwatch.observer/filing/0001213900-25-001156#claim-4d653982e8fabae094561a163c06f05c06f30d20","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/0001213900-25-001156-index.htm"},{"fact_type":"executive_change","fact_key":"85daadad7a","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-10-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-11","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Shami Patel was appointed as Class III Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On October 9, 2024, the Board of Directors (the “ Board ”) of the Company appointed Shami Patel to the Board as a Class III director, effective October 11, 2024, to fill the vacancy created by Dr. Corey’s resignation","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-087267","anchor_url":"https://secwatch.observer/filing/0001213900-24-087267#claim-85daadad7a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024087267/0001213900-24-087267-index.htm"},{"fact_type":"governance_change","fact_key":"22ded167a8d27ddb5ee415454837a3f803e9bb34","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-10-02T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-09-25","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Designations creating Series C Convertible Preferred Stock"},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations creating Series C Convertible Preferred Stock (effective 2024-09-25).","evidence_excerpt":"On September 25, 2024, CERo Therapeutics Holdings, Inc. (the “ Company ”) filed a Certificate of Designations of Series C Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designations ”), thereby creating a new series of preferred stock of the Company designated as “Series C Convertible Preferred Stock.”","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-084200","anchor_url":"https://secwatch.observer/filing/0001213900-24-084200#claim-22ded167a8d27ddb5ee415454837a3f803e9bb34","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084200/0001213900-24-084200-index.htm"},{"fact_type":"executive_change","fact_key":"6f838387cd","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-10-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Andrew Albert \"Al\" Kucharchuk was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 30, 2024, the Board appointed Andrew Albert “Al” Kucharchuk as Chief Financial Officer of the Company, effective October 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-084337","anchor_url":"https://secwatch.observer/filing/0001213900-24-084337#claim-6f838387cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm"},{"fact_type":"executive_change","fact_key":"04dac54f9a","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-10-02T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-30","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Andrew Albert \"Al\" Kucharchuk","successor_named":true},"claim":"Charles R. Carter resigned as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"As previously announced, Charles R. Carter resigned from his position as Chief Financial Officer, effective on September 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-084337","anchor_url":"https://secwatch.observer/filing/0001213900-24-084337#claim-04dac54f9a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm"},{"fact_type":"executive_change","fact_key":"c0d01b949f","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-10-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-01","interim":false,"role":"Chief Development Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Kristen Pierce was appointed as Chief Development Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 30, 2024, the Board of Directors (the “ Board ”) of CERo Therapeutics Holdings, Inc. (the “ Company ”) appointed Kristen Pierce, Ph.D., as Chief Development Officer of the Company, effective October 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-084337","anchor_url":"https://secwatch.observer/filing/0001213900-24-084337#claim-c0d01b949f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm"},{"fact_type":"executive_change","fact_key":"91340a313f","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-09-25T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":true,"role":"Interim Chairman and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Chris Ehrlich was appointed as Interim Chairman and Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Chris Ehrlich, the Vice Chairman of the Board, agreed to serve as Interim Chairman and Chief Executive Officer while the Board searches for a permanent replacement.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-081792","anchor_url":"https://secwatch.observer/filing/0001213900-24-081792#claim-91340a313f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm"},{"fact_type":"executive_change","fact_key":"c76fa41ee8","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-09-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-23","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Daniel Corey resigned as director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-081792","anchor_url":"https://secwatch.observer/filing/0001213900-24-081792#claim-c76fa41ee8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm"},{"fact_type":"executive_change","fact_key":"294fcef3f9","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-09-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-23","interim":false,"role":"Chief Technology Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Daniel Corey resigned as Chief Technology Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-081792","anchor_url":"https://secwatch.observer/filing/0001213900-24-081792#claim-294fcef3f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm"},{"fact_type":"executive_change","fact_key":"d9a5d50e4e","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-09-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-30","interim":true,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Chris Ehrlich","successor_named":true},"claim":"Brian G. Atwood resigned as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 22, 2024, the Company’s Chairman and Chief Executive Officer, Brian G. Atwood, informed the Board of his resignation as Chief Executive Officer, effective at a date to be determined, which shall be no later than September 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-081792","anchor_url":"https://secwatch.observer/filing/0001213900-24-081792#claim-d9a5d50e4e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm"},{"fact_type":"executive_change","fact_key":"b44936b011","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-09-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-30","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Charles R. Carter resigned as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 17, 2024, the Chief Financial Officer of CERo Therapeutics Holdings, Inc. (the “ Company ”), Charles R. Carter, informed the Board of Directors of the Company (the “ Board ”) that he expects to accept a new position with another publicly-traded company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-081023","anchor_url":"https://secwatch.observer/filing/0001213900-24-081023#claim-b44936b011","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081023/0001213900-24-081023-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a2208a92c4265f384aa436ad68cf60ac92d9a845","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-05-03T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-10-29","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"50000000","notice_date":"2024-05-02","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(b)(2)(A)"],"rules_cited_in_text":true},"claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).","evidence_excerpt":"May 2, 2024, CERo\nTherapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), received a letter (the “ Letter ”)\nfrom the staff at The Nasdaq Global Market (“ Nasdaq ”) notifying the Company that, for the 30 consecutive trading\ndays prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market\nValue of Listed Securities” (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which\nis required for continued listing of the Company’s common stock on Nasdaq. The Letter is only a notification of deficiency, not\nof","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-039644","anchor_url":"https://secwatch.observer/filing/0001213900-24-039644#claim-a2208a92c4265f384aa436ad68cf60ac92d9a845","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024039644/0001213900-24-039644-index.htm"},{"fact_type":"shareholder_vote","fact_key":"07dbb5ccfcc8d89bcc7c07ca5145494457fda367","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-30","outcome":"passed","proposal_text":"To approve an amendment to the Company’s 2024 Equity Incentive Plan (the “Plan”), as amended, amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shar","proposal_type":"equity_plan","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"5,614","votes_against":"134,041","votes_for":"8,234,447","votes_withheld":null}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve an amendment to the Company’s 2024 Equity Incentive Plan (the “Plan”), as amended, amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shar at the 2024-04-30 meeting.","evidence_excerpt":"Proposal 4. To approve an amendment to the Company’s 2024 Equity Incentive Plan (the “Plan”), as amended, amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shares. FOR ABSTAIN AGAINST 8,234,447 5,614 134,041","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-038497","anchor_url":"https://secwatch.observer/filing/0001213900-24-038497#claim-07dbb5ccfcc8d89bcc7c07ca5145494457fda367","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6488bb431fc58a6072a371c71738521b467ee0e3","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-30","outcome":"passed","proposal_text":"To approve, subject to certain conditions, the issuance of shares of Common Stock, in accordance with Nasdaq Listing Rule 5635, pursuant to the Committed Equity Financings (as defined in the Proxy Statement).","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"6,581","votes_against":"63,815","votes_for":"8,303,706","votes_withheld":null}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve, subject to certain conditions, the issuance of shares of Common Stock, in accordance with Nasdaq Listing Rule 5635, pursuant to the Committed Equity Financings (as defined in the Proxy Statement). at the 2024-04-30 meeting.","evidence_excerpt":"Proposal 3. To approve, subject to certain conditions, the issuance of shares of Common Stock, in accordance with Nasdaq Listing Rule 5635, pursuant to the Committed Equity Financings (as defined in the Proxy Statement). FOR ABSTAIN AGAINST 8,303,706 6,581 63,815","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-038497","anchor_url":"https://secwatch.observer/filing/0001213900-24-038497#claim-6488bb431fc58a6072a371c71738521b467ee0e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1aadf4937f4a2b9be90213310eebb2a3f199f04d","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-30","outcome":"passed","proposal_text":"To approve, subject to certain conditions, the issuance of the Common Stock, in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Company’s Series A convertible preferred stock, par value $0.0001 per share (“Series A Preferred Stock”), (ii) the conversion of the Company’s Seri","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"6,621","votes_against":"58,715","votes_for":"8,308,766","votes_withheld":null}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve, subject to certain conditions, the issuance of the Common Stock, in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Company’s Series A convertible preferred stock, par value $0.0001 per share (“Series A Preferred Stock”), (ii) the conversion of the Company’s Seri at the 2024-04-30 meeting.","evidence_excerpt":"Proposal 2. To approve, subject to certain conditions, the issuance of the Common Stock, in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Company’s Series A convertible preferred stock, par value $0.0001 per share (“Series A Preferred Stock”), (ii) the conversion of the Company’s Series B convertible preferred stock, par value $0.0001 per share, (iii) the exercise of warrants to purchase Common Stock and (iv) the exercise of warrants to purchase 2,500 shares of Series A Preferred Stock and conversion of the underlying Series A Preferred Stock. FOR ABSTAIN AGAINST 8,308,766 6,621 58,715","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-038497","anchor_url":"https://secwatch.observer/filing/0001213900-24-038497#claim-1aadf4937f4a2b9be90213310eebb2a3f199f04d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm"},{"fact_type":"shareholder_vote","fact_key":"98831af08a555366eaa5026a0f4a347995e04130","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-30","outcome":"passed","proposal_text":"To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the 2024 fiscal year.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"7,562","votes_against":"44,878","votes_for":"8,321,662","votes_withheld":null}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the 2024 fiscal year. at the 2024-04-30 meeting.","evidence_excerpt":"Proposal 1. To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the 2024 fiscal year. FOR ABSTAIN AGAINST 8,321,662 7,562 44,878","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-038497","anchor_url":"https://secwatch.observer/filing/0001213900-24-038497#claim-98831af08a555366eaa5026a0f4a347995e04130","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm"},{"fact_type":"material_agreement","fact_key":"5d820db058f29197c9ce5240a4e8770991e3af68","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13","effective_date":"2024-02-23","item_codes_triggered":["1.01"],"value_text":"up to $25 million"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Purchase Agreement with Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13 valued at up to $25 million (effective 2024-02-23).","evidence_excerpt":"On February 23, 2024, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), entered into a purchase agreement (the “Purchase Agreement ”) with Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13 (“ Arena ”), pursuant to which Arena has committed to purchase up to $25 million (the “ Commitment Amount ”) of the Company’s shares of common stock, par value $0.0001 per share (the “ Common Stock ”), subject to the satisfaction of the conditions in the Purchase Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017770","anchor_url":"https://secwatch.observer/filing/0001213900-24-017770#claim-5d820db058f29197c9ce5240a4e8770991e3af68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/0001213900-24-017770-index.htm"},{"fact_type":"ma_transaction","fact_key":"290df82591dfa460c2f0e3dd19d263dcdf7f75e1","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2024-02-14","consideration_text":"Issuance of 8,457,653 shares of Common Stock (including 3,075,000 Earnout Shares and 382,653 shares issuable upon exercise of rollover options or warrants)","counterparty":"Phoenix Biotech Acquisition Corp. (PBAX)","effective_date":"2024-02-14","item_codes_triggered":["2.01","5.01"]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. underwent a change of control involving Phoenix Biotech Acquisition Corp. (PBAX) for Issuance of 8,457,653 shares of Common Stock (including 3,075,000 Earnout Shares and 382,653 shares issuable upon exercise of rollover options or warrants) (closed 2024-02-14).","evidence_excerpt":"the earlier of such forfeiture or the expiration\n of the earnout period. As\nconsideration for the Business Combination, the Company issued to CERo stockholders an aggregate of 8,457,653 shares of Common Stock,\nincluding 3,075,000 Earnout Shares and 382,653 shares issuable upon exercise of rollover options or warrants. The foregoing\n description of the Business","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-290df82591dfa460c2f0e3dd19d263dcdf7f75e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"material_agreement","fact_key":"50493393878b9eb0757c7ecf8829e9226896abd2","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Sponsor Share Forfeiture Agreement","agreement_type":"other","counterparty":null,"effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Sponsor Share Forfeiture Agreement.","evidence_excerpt":"Sponsor Share Forfeiture Agreement At Closing, the Sponsor entered into the Sponsor Share Forfeiture Agreement,\npursuant to which, upon the terms and subj","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-50493393878b9eb0757c7ecf8829e9226896abd2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"material_agreement","fact_key":"87d5ed7e937fe65fd253825c8d7dc0dc7b682d33","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"ELOC Registration Rights Agreement","agreement_type":"equity_purchase","counterparty":null,"effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into ELOC Registration Rights Agreement.","evidence_excerpt":"Concurrent with the execution of the Common Stock Purchase Agreement, the Company entered into a registration rights agreement with the Lead Investor (the “ ELOC Registration Rights Agreement ”),","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-87d5ed7e937fe65fd253825c8d7dc0dc7b682d33","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"material_agreement","fact_key":"4a011a8172898389f528bc7ecbdcdaa768c2ceed","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Common Stock Purchase Agreement","agreement_type":"equity_purchase","counterparty":null,"effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Common Stock Purchase Agreement.","evidence_excerpt":"BAX entered into a common stock purchase agreement (the “ Common Stock Purchase Agreement ”) with the Lead Investor,\npursuant to which the Company may sell and issue, and the Lead Investor is obligated to purchase, up to the greater of (i) 2,977,070 shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-4a011a8172898389f528bc7ecbdcdaa768c2ceed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"5cf03dd7ef","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robyn Rapaport was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"electing each of Lindsey Rolfe and Robyn Rapaport to serve as a director","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-5cf03dd7ef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"e6a337c65f","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lindsey Rolfe was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"electing each of Lindsey Rolfe and Robyn Rapaport to serve as a director","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-e6a337c65f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"8963e8121f","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Chief Technical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Mr. Corey was appointed as Chief Technical Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Corey was appointed as the Company’s Chief Technical Officer","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-8963e8121f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"dfd1b318ce","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Mr. Carter was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Carter was appointed as the Company’s Chief Financial Officer","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-dfd1b318ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"ea011176d0","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Mr. Atwood was appointed as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Atwood was appointed as the Company’s Chief Executive Officer","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-ea011176d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"f3f9371c80","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mr. Ehrlich was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-f3f9371c80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"3f82cfef7e","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mr. Corey was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-3f82cfef7e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"eb136a2c6b","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ms. LaPorte was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-eb136a2c6b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"c29dca26da","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mr. Atwood was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-c29dca26da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"a07d623c2f","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mr. Byrnes was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-a07d623c2f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"3f546cd728","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ms. Loewy resigned as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-3f546cd728","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"executive_change","fact_key":"b30f855f3d","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ms. Kosacz resigned as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-017157","anchor_url":"https://secwatch.observer/filing/0001213900-24-017157#claim-b30f855f3d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm"},{"fact_type":"governance_change","fact_key":"def693284d1d5d359465a4981e3c854a061c58eb","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"change_type":"shell_status","effective_date":"2024-02-14","item_codes_triggered":["5.06"],"summary_text":"Company ceased being a shell company as a result of the Business Combination"},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: Company ceased being a shell company as a result of the Business Combination (effective 2024-02-14).","evidence_excerpt":"As a result of the Business Combination, the Company ceased being a shell company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-def693284d1d5d359465a4981e3c854a061c58eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"governance_change","fact_key":"116c8e7507684d239fff0c059a3d589c1354416e","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-02-14","item_codes_triggered":["5.03"],"summary_text":"Adopted amended and restated bylaws in connection with Business Combination"},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: Adopted amended and restated bylaws in connection with Business Combination (effective 2024-02-14).","evidence_excerpt":"and (ii) adopted amended and restated bylaws (as amended, the “ Bylaws ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-116c8e7507684d239fff0c059a3d589c1354416e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"governance_change","fact_key":"4b39577405a7944b4f4a6da4e85b61ba28a49fdc","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-02-14","item_codes_triggered":["5.03"],"summary_text":"Filed second amended and restated certificate of incorporation in connection with Business Combination"},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: Filed second amended and restated certificate of incorporation in connection with Business Combination (effective 2024-02-14).","evidence_excerpt":"the Company (i) filed a second amended and restated certificate of incorporation with the Secretary of State of the State of Delaware (as amended, the “ Certificate of Incorporation ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-4b39577405a7944b4f4a6da4e85b61ba28a49fdc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"ma_transaction","fact_key":"983a34e5b4e7c5ad52d465ca3c4c07e73383c46c","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-02-14","consideration_text":null,"counterparty":"CERo Therapeutics, Inc.","effective_date":"2024-02-14","item_codes_triggered":["2.01","5.01"]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. completed an acquisition involving CERo Therapeutics, Inc. (closed 2024-02-14).","evidence_excerpt":"On February 14, 2024 (the “ Closing Date ”), Phoenix Biotech Acquisition Corp., a Delaware corporation (“ PBAX ” and, after the consummation of the Business Combination (as defined below), the “ Company ”), completed the previously announced acquisition of CERo Therapeutics, Inc., a Delaware corporation (“ CERo ”), pursuant to the business combination agreement and plan of reorganization","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-983a34e5b4e7c5ad52d465ca3c4c07e73383c46c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"material_agreement","fact_key":"dbdb6796a61ed6c27b44b421897c899eabf1e458","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Common Stock Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Keystone Capital Partners, LLC","effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Common Stock Purchase Agreement with Keystone Capital Partners, LLC.","evidence_excerpt":"the Company entered into a common stock purchase agreement (the \" Common Stock Purchase Agreement \") with Keystone Capital Partners, LLC (the \" ELOC Investor \")","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-dbdb6796a61ed6c27b44b421897c899eabf1e458","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"75b41fd182","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robyn Rapaport was elected as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On February 14, 2024, the Board increase the size of the Board to seven directors and filled the vacancies caused thereby by electing each of Lindsey Rolfe and Robyn Rapaport to serve as a director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-75b41fd182","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"dcb57ac9e1","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lindsey Rolfe was elected as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On February 14, 2024, the Board increase the size of the Board to seven directors and filled the vacancies caused thereby by electing each of Lindsey Rolfe and Robyn Rapaport to serve as a director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-dcb57ac9e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"76a51fd1c8","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Mr. Carter was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Carter was appointed as the Company's Chief Financial Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-76a51fd1c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"a65ff4ec1d","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Chief Technical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Mr. Corey was appointed as Chief Technical Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Corey was appointed as the Company's Chief Technical Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-a65ff4ec1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"484b88f297","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Mr. Atwood was appointed as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Atwood was appointed as the Company's Chief Executive Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-484b88f297","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"0f35d07f1c","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mr. Ehrlich was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-0f35d07f1c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"977cda776f","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mr. Corey was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-977cda776f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"bf2461d5d3","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ms. LaPorte was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-bf2461d5d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"1109a25597","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mr. Atwood was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-1109a25597","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"2d4c09f823","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mr. Byrnes was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-2d4c09f823","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"f88a21bf01","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ms. Loewy resigned as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-f88a21bf01","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"executive_change","fact_key":"ca76379954","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ms. Kosacz resigned as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-014197","anchor_url":"https://secwatch.observer/filing/0001213900-24-014197#claim-ca76379954","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm"},{"fact_type":"material_agreement","fact_key":"4b1e6e8a26a5c8860dd83c4f84667fa5751d9183","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Second BCA Amendment","agreement_type":"merger","counterparty":"Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., CERo Therapeutics, Inc.","effective_date":"2024-02-13","item_codes_triggered":["1.01"],"value_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. amended Second BCA Amendment with Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., CERo Therapeutics, Inc. (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, the parties to the Business Combination Agreement entered into Amendment No. 2 to the Business Combination Agreement (the \" Second BCA Amendment \") to create two additional pools of earnout shares of common stock, par value $0.0001 per share (\" Common Stock \"), one pool of which will contain 875,000 shares, which will be fully vested at closing of the Business Combination and which are being issued as an offset to the agreement by Phoenix Biotech Sponsor, LLC to forfeit an offsetting number of shares, and one pool of which will contain 1,000,000 shares, which will be fully vested upon the achievement of certain regulatory milestone-based earnout targets and make certain other technical changes to the timing and process for issuance of the 1,200,000 shares of Common Stock subject to the other earn-out conditions set forth in the Business Combination Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-013804","anchor_url":"https://secwatch.observer/filing/0001213900-24-013804#claim-4b1e6e8a26a5c8860dd83c4f84667fa5751d9183","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024013804/0001213900-24-013804-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1083cd71287e7dc7647772d36032322016115c37","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"To approve the 2024 Employee Stock Purchase Plan, which will become effective as of and contingent on the consummation of the Business Combination.","proposal_type":"equity_plan","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,588","votes_against":"0","votes_for":"5,493,678","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve the 2024 Employee Stock Purchase Plan, which will become effective as of and contingent on the consummation of the Business Combination. at the 2024-02-08 meeting.","evidence_excerpt":"Proposal 7. To approve the 2024 Employee Stock Purchase Plan, which will become effective as of and contingent on the consummation of the Business Combination. FOR ABSTAIN AGAINST 5,493,678 10,588 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-1083cd71287e7dc7647772d36032322016115c37","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a87f18c68775c6dcde46cab3a60d0f916d419814","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"To approve the 2024 Equity Incentive Plan, which will become effective as of and contingent on the consummation of the Business Combination.","proposal_type":"equity_plan","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,588","votes_against":"0","votes_for":"5,493,678","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve the 2024 Equity Incentive Plan, which will become effective as of and contingent on the consummation of the Business Combination. at the 2024-02-08 meeting.","evidence_excerpt":"Proposal 6. To approve the 2024 Equity Incentive Plan, which will become effective as of and contingent on the consummation of the Business Combination. FOR ABSTAIN AGAINST 5,493,678 10,588 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-a87f18c68775c6dcde46cab3a60d0f916d419814","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"865ae5680c2628a21e435768be3e65d6041f2fc9","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"To approve the appointment of five directors who, upon consummation of the Business Combination, will become directors of New CERo.","proposal_type":"director_election","results":[{"broker_non_votes":"0","subject":"Michael Byrnes","votes_abstain":"12","votes_against":"0","votes_for":"5,504,254","votes_withheld":"0"},{"broker_non_votes":"0","subject":"Brian Atwood","votes_abstain":"12","votes_against":"0","votes_for":"5,504,254","votes_withheld":"0"},{"broker_non_votes":"0","subject":"Kathleen LaPorte","votes_abstain":"0","votes_against":"0","votes_for":"5,504,266","votes_withheld":"0"},{"broker_non_votes":"0","subject":"Daniel Corey","votes_abstain":"12","votes_against":"0","votes_for":"5,504,254","votes_withheld":"0"},{"broker_non_votes":"0","subject":"Chris Ehrlich","votes_abstain":"12","votes_against":"0","votes_for":"5,504,254","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve the appointment of five directors who, upon consummation of the Business Combination, will become directors of New CERo. at the 2024-02-08 meeting.","evidence_excerpt":"Proposal 5. To approve the appointment of five directors who, upon consummation of the Business Combination, will become directors of New CERo. (1) Michael Byrnes FOR ABSTAIN AGAINST 5,504,254 12 0 2 (2) Brian Atwood FOR ABSTAIN AGAINST 5,504,254 12 0 (3) Kathleen LaPorte FOR ABSTAIN AGAINST 5,504,266 0 0 (4) Daniel Corey FOR ABSTAIN AGAINST 5,504,254 12 0 (5) Chris Ehrlich FOR ABSTAIN AGAINST 5,504,254 12 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-865ae5680c2628a21e435768be3e65d6041f2fc9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"231f2d994b791dc83e578172242117cf2efbd52d","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"To approve, for purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the issuance of shares of Class A common stock to CERo shareholders pursuant to the Business Combination Agreement, including the potential issuance of an additional 1,200,000 earnout shares of Class A","proposal_type":"merger_approval","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,588","votes_against":"0","votes_for":"5,493,678","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve, for purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the issuance of shares of Class A common stock to CERo shareholders pursuant to the Business Combination Agreement, including the potential issuance of an additional 1,200,000 earnout shares of Class A at the 2024-02-08 meeting.","evidence_excerpt":"Proposal 4. To approve, for purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the issuance of shares of Class A common stock to CERo shareholders pursuant to the Business Combination Agreement, including the potential issuance of an additional 1,200,000 earnout shares of Class A common stock. FOR ABSTAIN AGAINST 5,493,678 10,588 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-231f2d994b791dc83e578172242117cf2efbd52d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f77b077e437af23fb1cb7d4bf42da373e0cac9a2","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"Advisory Charter Proposal F — to remove the provision that allows stockholders to act by written consent as opposed to holding a stockholders meeting.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,588","votes_against":"0","votes_for":"5,493,678","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Advisory Charter Proposal F — to remove the provision that allows stockholders to act by written consent as opposed to holding a stockholders meeting. at the 2024-02-08 meeting.","evidence_excerpt":"Advisory Charter Proposal F — to remove the provision that allows stockholders to act by written consent as opposed to holding a stockholders meeting. FOR ABSTAIN AGAINST 5,493,678 10,588 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-f77b077e437af23fb1cb7d4bf42da373e0cac9a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4444c6b974fd3629440788a9acce9288d6fea2d2","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"Advisory Charter Proposal E — to make New CERo’s corporate existence perpetual instead of requiring PBAX to be dissolved and liquidated by April 8, 2024 (or such later date as may be approved by PBAX’s stockholders), and to omit from the Proposed Charter the various provisions applicable only to spe","proposal_type":"say_on_pay","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,588","votes_against":"0","votes_for":"5,493,678","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Advisory Charter Proposal E — to make New CERo’s corporate existence perpetual instead of requiring PBAX to be dissolved and liquidated by April 8, 2024 (or such later date as may be approved by PBAX’s stockholders), and to omit from the Proposed Charter the various provisions applicable only to spe at the 2024-02-08 meeting.","evidence_excerpt":"Advisory Charter Proposal E — to make New CERo’s corporate existence perpetual instead of requiring PBAX to be dissolved and liquidated by April 8, 2024 (or such later date as may be approved by PBAX’s stockholders), and to omit from the Proposed Charter the various provisions applicable only to special purpose acquisition companies; and FOR ABSTAIN AGAINST 5,493,678 10,588 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-4444c6b974fd3629440788a9acce9288d6fea2d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b7472753b37353f184209e99d52ab7a7dc481585","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"Advisory Charter Proposal D — to provide that certain amendments to provisions of the Proposed Charter will require the approval of at least 66 2/3% of New CERo’s then-outstanding shares of capital stock entitled to vote on such amendment and of each class entitled to vote thereon as a class;","proposal_type":"say_on_pay","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,600","votes_against":"0","votes_for":"5,493,666","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Advisory Charter Proposal D — to provide that certain amendments to provisions of the Proposed Charter will require the approval of at least 66 2/3% of New CERo’s then-outstanding shares of capital stock entitled to vote on such amendment and of each class entitled to vote thereon as a class; at the 2024-02-08 meeting.","evidence_excerpt":"Advisory Charter Proposal D — to provide that certain amendments to provisions of the Proposed Charter will require the approval of at least 66 2/3% of New CERo’s then-outstanding shares of capital stock entitled to vote on such amendment and of each class entitled to vote thereon as a class; FOR ABSTAIN AGAINST 5,493,666 10,600 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-b7472753b37353f184209e99d52ab7a7dc481585","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"702f663e6b6bb49a1e7c9afc104e1d5546b1cac9","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"Advisory Charter Proposal C — to create a classified board of directors consisting of three classes, Class I, Class II and Class III, with members of each class elected for three-year terms expiring in sequential years;","proposal_type":"say_on_pay","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,600","votes_against":"0","votes_for":"5,493,666","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Advisory Charter Proposal C — to create a classified board of directors consisting of three classes, Class I, Class II and Class III, with members of each class elected for three-year terms expiring in sequential years; at the 2024-02-08 meeting.","evidence_excerpt":"Advisory Charter Proposal C — to create a classified board of directors consisting of three classes, Class I, Class II and Class III, with members of each class elected for three-year terms expiring in sequential years; FOR ABSTAIN AGAINST 5,493,666 10,600 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-702f663e6b6bb49a1e7c9afc104e1d5546b1cac9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"076f2e88ade51f9928ea114ce2a1f36ef632c951","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"Advisory Charter Proposal B — to increase New CERo’s capitalization so that it will have 1,000,000,000 authorized shares of a single class of common stock and 10,000,000 authorized shares of preferred stock;","proposal_type":"say_on_pay","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,600","votes_against":"0","votes_for":"5,493,666","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Advisory Charter Proposal B — to increase New CERo’s capitalization so that it will have 1,000,000,000 authorized shares of a single class of common stock and 10,000,000 authorized shares of preferred stock; at the 2024-02-08 meeting.","evidence_excerpt":"Advisory Charter Proposal B — to increase New CERo’s capitalization so that it will have 1,000,000,000 authorized shares of a single class of common stock and 10,000,000 authorized shares of preferred stock; FOR ABSTAIN AGAINST 5,493,666 10,600 0 1","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-076f2e88ade51f9928ea114ce2a1f36ef632c951","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ec7a0a49bd9fe72b9eb1bc3804e11c4ce737e572","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"Advisory Charter Proposal A — to change the corporate name of New CERo to “CERo Therapeutics Holdings, Inc.” on and from the time of the Business Combination;","proposal_type":"say_on_pay","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,588","votes_against":"0","votes_for":"5,493,678","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Advisory Charter Proposal A — to change the corporate name of New CERo to “CERo Therapeutics Holdings, Inc.” on and from the time of the Business Combination; at the 2024-02-08 meeting.","evidence_excerpt":"Advisory Charter Proposal A — to change the corporate name of New CERo to “CERo Therapeutics Holdings, Inc.” on and from the time of the Business Combination; FOR ABSTAIN AGAINST 5,493,678 10,588 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-ec7a0a49bd9fe72b9eb1bc3804e11c4ce737e572","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e0361bad739cc6930b8da57541d799711de87126","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"To approve a proposed second amended and restated certificate of incorporation for New CERo (the “Proposed Charter”) and second amended and restated bylaws for New CERo, which will be in effect upon the closing of the Business Combination.","proposal_type":"charter_amendment","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,588","votes_against":"0","votes_for":"5,493,678","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve a proposed second amended and restated certificate of incorporation for New CERo (the “Proposed Charter”) and second amended and restated bylaws for New CERo, which will be in effect upon the closing of the Business Combination. at the 2024-02-08 meeting.","evidence_excerpt":"Proposal 2. To approve a proposed second amended and restated certificate of incorporation for New CERo (the “Proposed Charter”) and second amended and restated bylaws for New CERo, which will be in effect upon the closing of the Business Combination. FOR ABSTAIN AGAINST 5,493,678 10,588 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-e0361bad739cc6930b8da57541d799711de87126","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7bd8361ac8678e5ffecb335b24b99e0bbdecf35b","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-02-08","outcome":"passed","proposal_text":"To (a) adopt and approve the Business Combination Agreement, pursuant to which Merger Sub will merge with and into CERo, with CERo surviving the merger as a wholly-owned subsidiary of the Company and (b) approve such merger and the other transactions contemplated by the Business Combination Agreemen","proposal_type":"merger_approval","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,588","votes_against":"0","votes_for":"5,493,678","votes_withheld":"0"}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To (a) adopt and approve the Business Combination Agreement, pursuant to which Merger Sub will merge with and into CERo, with CERo surviving the merger as a wholly-owned subsidiary of the Company and (b) approve such merger and the other transactions contemplated by the Business Combination Agreemen at the 2024-02-08 meeting.","evidence_excerpt":"Proposal 1. To (a) adopt and approve the Business Combination Agreement, pursuant to which Merger Sub will merge with and into CERo, with CERo surviving the merger as a wholly-owned subsidiary of the Company and (b) approve such merger and the other transactions contemplated by the Business Combination Agreement, and (c) adopt and approve each Ancillary Document (as defined in the Business Combination Agreement) to which the Company is a party and approve all transactions contemplated therein. FOR ABSTAIN AGAINST 5,493,678 10,588 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-012571","anchor_url":"https://secwatch.observer/filing/0001213900-24-012571#claim-7bd8361ac8678e5ffecb335b24b99e0bbdecf35b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm"},{"fact_type":"material_agreement","fact_key":"50b72a9f8d24edf9f26d7643c06d3e0b25ee0ea1","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"an accredited investor","effective_date":"2024-02-05","item_codes_triggered":["1.01"],"value_text":"$2.0 million"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Securities Purchase Agreement with an accredited investor valued at $2.0 million (effective 2024-02-05).","evidence_excerpt":"On February 5, 2024, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-010227","anchor_url":"https://secwatch.observer/filing/0001213900-24-010227#claim-50b72a9f8d24edf9f26d7643c06d3e0b25ee0ea1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm"},{"fact_type":"material_agreement","fact_key":"dd79d2d375d9bf664fceb83a93cc06341b6e882b","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-06T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 1 to the Business Combination Agreement","agreement_type":"merger","counterparty":"Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc.","effective_date":"2024-02-05","item_codes_triggered":["1.01"],"value_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. amended Amendment No. 1 to the Business Combination Agreement with Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc. (effective 2024-02-05).","evidence_excerpt":"arties entered into Amendment No. 1 to the Business Combination Agreement (the “ Amendment ”) to, among other things,\n(i) remove the minimum cash condition, (ii) modify the stock-price based milestones such that (a) the trading price condition for the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-010227","anchor_url":"https://secwatch.observer/filing/0001213900-24-010227#claim-dd79d2d375d9bf664fceb83a93cc06341b6e882b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm"},{"fact_type":"governance_change","fact_key":"b0dbdb9b48eefea83a9578ff66f799a5320459c6","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-01-03","item_codes_triggered":["5.03"],"summary_text":"Amended charter to allow board to extend business combination deadline up to three additional months, and to provide redemption rights without tender offer rules."},"claim":"CERO THERAPEUTICS HOLDINGS, INC.: Amended charter to allow board to extend business combination deadline up to three additional months, and to provide redemption rights without tender offer rules (effective 2024-01-03).","evidence_excerpt":"On January 3, 2024, the Company’s stockholders approved an amendment (the “ Charter Amendment ”) to the Company’s amended and restated certificate of incorporation, as amended by the First Amendment dated December 20, 2022 and the Second Amendment dated July 7, 2023 (the “ Charter ”), to provide its board of directors the ability to extend the date by which the Company has to consummate a business combination up to three times for one month each time, for a maximum of three additional months.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-001511","anchor_url":"https://secwatch.observer/filing/0001213900-24-001511#claim-b0dbdb9b48eefea83a9578ff66f799a5320459c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024001511/0001213900-24-001511-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ddf831821f9a508ea61c0c8fa1c35d771dfe1bbb","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-03","outcome":"passed","proposal_text":"Trust Amendment Proposal - to amend the Trust Agreement to extend the business combination period","proposal_type":"merger_approval","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"11,082","votes_for":"5,538,811","votes_withheld":null}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Trust Amendment Proposal - to amend the Trust Agreement to extend the business combination period at the 2024-01-03 meeting.","evidence_excerpt":"Proposal 2 - The Trust Amendment Proposal - a proposal to amend the Trust Agreement to extend the business combination period up to three times for one month each time from January 8, 2024 to February 8, 2024, March 8, 2024 or April 8, 2024. For Against Abstain 5,538,811 11,082 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-001511","anchor_url":"https://secwatch.observer/filing/0001213900-24-001511#claim-ddf831821f9a508ea61c0c8fa1c35d771dfe1bbb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024001511/0001213900-24-001511-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3b2c843de5c4a477067bb81a8c7267307a921a4e","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-03","outcome":"passed","proposal_text":"Charter Amendment Proposal - to amend the Charter to extend the business combination period","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"11,070","votes_for":"5,538,823","votes_withheld":null}]},"claim":"CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Charter Amendment Proposal - to amend the Charter to extend the business combination period at the 2024-01-03 meeting.","evidence_excerpt":"Proposal 1 - The Charter Amendment Proposal - a proposal to amend the Charter to (a) provide its board of directors the ability to extend the date by which the Company has to consummate a business combination up to three times for one month each time from January 8, 2024 to February 8, 2024, March 8, 2024 or April 8, 2024 and (b) allow for the Company to provide redemption rights to the Company’s public stockholders in accordance with the requirements of the charter without complying with the tender offer rules. For Against Abstain 5,538,823 11,070 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-001511","anchor_url":"https://secwatch.observer/filing/0001213900-24-001511#claim-3b2c843de5c4a477067bb81a8c7267307a921a4e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024001511/0001213900-24-001511-index.htm"},{"fact_type":"material_agreement","fact_key":"45cb5c2853b2a2fe50096a042b5af856b827caa7","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Trust Agreement Amendment","agreement_type":"other","counterparty":"Continental Stock Transfer and Trust Company","effective_date":"2024-01-03","item_codes_triggered":["1.01"],"value_text":null},"claim":"CERO THERAPEUTICS HOLDINGS, INC. amended Trust Agreement Amendment with Continental Stock Transfer and Trust Company (effective 2024-01-03).","evidence_excerpt":"Trust Agreement Amendment At the Special Meeting,\nthe Company’s stockholders approved a proposal to amend (the “ Trust Agreement Amendment ”) the Investment Management","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001213900-24-001511","anchor_url":"https://secwatch.observer/filing/0001213900-24-001511#claim-45cb5c2853b2a2fe50096a042b5af856b827caa7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024001511/0001213900-24-001511-index.htm"},{"fact_type":"debt_financing","fact_key":"673b704afa9d18ae671e0b863fab44ef156939a5","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2023-12-11T23:59:59+00:00","payload":{"counterparty":"Phoenix Biotech Sponsor, LLC","effective_date":"2023-12-08","event":"amendment","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$1,600,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. amended loan of $1,600,000 with Phoenix Biotech Sponsor, LLC.","evidence_excerpt":"On December 8, 2023, the Company and the Lender amended the Promissory Note to increase the aggregate principal amount of the Promissory Note from $1,500,000 to $1,600,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-094779","anchor_url":"https://secwatch.observer/filing/0001213900-23-094779#claim-673b704afa9d18ae671e0b863fab44ef156939a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023094779/0001213900-23-094779-index.htm"},{"fact_type":"material_agreement","fact_key":"4d40e045160bfa5418f0576633416dad7a40cfd7","cik":1870404,"ticker":"CERO","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2023-12-11T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Promissory Note","agreement_type":"credit_facility","counterparty":"Phoenix Biotech Sponsor, LLC","effective_date":"2023-12-08","item_codes_triggered":["1.01"],"value_text":"$1,500,000 to $1,600,000"},"claim":"CERO THERAPEUTICS HOLDINGS, INC. amended Promissory Note with Phoenix Biotech Sponsor, LLC valued at $1,500,000 to $1,600,000 (effective 2023-12-08).","evidence_excerpt":"On December 8, 2023, the Company and the Lender amended the Promissory Note to increase the aggregate principal amount of the Promissory Note from $1,500,000 to $1,600,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-094779","anchor_url":"https://secwatch.observer/filing/0001213900-23-094779#claim-4d40e045160bfa5418f0576633416dad7a40cfd7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023094779/0001213900-23-094779-index.htm"}]}